1.12

4.20% -0.07

Jaguar Health Inc (JAGX)

Overview News Price History Financials Why JAGX Down? Discussions Forecast Stock Split

Jaguar Health Inc stock is traded at $1.12, with a volume of 100.09K. It is down -4.20% in the last 24 hours and down -31.33% over the past month. Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Previous Close:

$1.19

Open:

$1.24

24h Volume:

100.09K

Relative Volume:

0.47

Market Cap:

$4.68M

Revenue:

$10.48M

Net Income/Loss:

$-37.74M

P/E Ratio:

-0.0692

EPS:

-16.1846

Net Cash Flow:

$-29.03M

1W Performance:

-20.83%

1M Performance:

-31.33%

6M Performance:

-58.99%

1Y Performance:

-94.70%

1-Day Range:

$1.115

$1.24

1-Week Range:

$1.12

$1.50

52-Week Range:

$1.00

$33.25

Jaguar Health Inc Stock (JAGX) Company Profile

Name

Jaguar Health Inc

Sector

Healthcare (1136)

Industry

Biotechnology (632)

Phone

415-371-8300

Address

200 PINE STREET SUITE 400, SAN FRANCISCO, CA

Employee

Twitter

@Jaguar_Health

Next Earnings Date

2024-11-12

Latest SEC Filings

JAGX's Discussions on Twitter

Compare JAGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JAGX Jaguar Health Inc	1.12	4.97M	10.48M	-37.74M	-29.03M	-16.18
VRTX Vertex Pharmaceuticals Inc	447.46	114.05B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	748.47	78.80B	14.25B	4.58B	3.88B	41.77
ARGX Argen X Se Adr	850.32	53.08B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	395.76	51.80B	3.21B	43.57M	221.36M	0.2405
INSM Insmed Inc	164.56	42.33B	447.02M	-1.18B	-906.14M	-6.1812

Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-07-21	Initiated	Cantor Fitzgerald	Overweight
Jul-11-17	Initiated	Rodman & Renshaw	Buy

Jaguar Health Inc Stock (JAGX) Latest News

03:32 AM

How Jaguar Health Inc. stock reacts to oil pricesWeekly Investment Report & Low Risk Investment Opportunities - Улправда

03:32 AM

Dec 16, 2025

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lubbock Avalanche-Journal

Dec 16, 2025

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Pensacola News Journal

Dec 16, 2025

Dec 15, 2025

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) - Hornell Evening Tribune

Dec 15, 2025

Jaguar Health director gets 5,870 RSUs and 5,870 options | JAGX SEC FilingForm 4 - Stock Titan

Dec 15, 2025

Jaguar Health submits abstract on crofelemer for short bowel syndrome By Investing.com - Investing.com Canada

Dec 15, 2025

Jaguar Health (JAGX) Advances Treatment for Short Bowel Syndrome - GuruFocus

Dec 15, 2025

Jaguar Health submits abstract on crofelemer for short bowel syndrome - Investing.com

Dec 15, 2025

Jaguar Health (NASDAQ: JAGX) advances crofelemer program in SBS-IF, MVID trials - Stock Titan

Dec 15, 2025

Dec 14, 2025

Jaguar Health executes strategic stock exchange agreements - MSN

Dec 14, 2025

Dec 12, 2025

Jaguar Health Executes Strategic Stock Exchange Agreements - TipRanks

Dec 12, 2025

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs - The Florida Times-Union

Dec 12, 2025

Dec 11, 2025